Neuroleptic malignant syndrome.
The neuroleptic malignant syndrome (NMS) is a potentially fatal syndrome characterized by diffuse muscular rigidity, pyrexia, sweating, cardiovascular instability, and elevated serum creatinine phosphokinase. NMS occurs in 2% of all patients exposed to neuroleptics (antipsychotic drugs). A case of successfully treated NMS is presented, and the typical symptomatic presentation, etiology, pathogenesis, and treatment options of this syndrome are described.
L W
LW
Reinish
R A
RA
Remick
Am J Psychiatry. 1986 Oct;143(10):1227-33
2876647
Can Med Assoc J. 1983 Apr 15;128(8):957-9
6831343
Br J Psychiatry. 1987 Jun;150:752-9
3307984
Can Med Assoc J. 1983 Oct 1;129(7):680-2
6616373
Can J Psychiatry. 1986 Feb;31(1):66-9
3948109
Can J Psychiatry. 1986 Oct;31(7):670-4
3536069
J Clin Psychopharmacol. 1986 Oct;6(5):257-73
2877012
Arch Intern Med. 1982 Jun;142(6):1183-5
6124221
Am J Psychiatry. 1986 Oct;143(10):1273-5
2876648